Allspring Global Investments
CDAK

Allspring Global Investments’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Allspring Global Investments’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,008
Closed -$25K – 3038
2022
Q1 		$25K Sell
4,008
-250
-6% -$1.57K ﹤0.01% 2922
2021
Q4 		$47K Buy
+4,258
New +$59K ﹤0.01% 2853

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Allspring Global Investments's CDAK Position: Q2 2022 in Review

Allspring Global Investments sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 4,008 shares — an estimated $25K sold.

Allspring Global Investments first reported a position in CDAK in Q4 2021 and held it in 2 quarters. The position peaked at $47K in Q4 2021. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • Allspring Global Investments reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 4,008 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $25K.
  • Allspring Global Investments first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Codiak BioSciences, Inc. Common Stock position peaked at $47K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.